Major histocompatibility complex-presented tumor antigen (null)

The queried "Tumor antigen presented by major histocompatibility complex" is not a single molecule or gene but a complex consisting of a peptide antigen (often derived from tumor-specific or tumor-associated mutated or aberrant proteins) bound to a major histocompatibility complex (MHC) molecule on the cell surface[1][3][4]. MHC class I molecules, present on nearly all nucleated cells, bind peptides of endogenous (mostly intracellular) origin and present them to cytotoxic CD8+ T cells, enabling immune recognition and destruction of abnormal cells, such as tumor cells[1][2][4][10]. MHC class II molecules, predominantly on professional antigen-presenting cells, present exogenous peptides to CD4+ T helper cells but can also participate in anti-tumor immunity[6]. The immunological synapse formed between the T cell receptor and the MHC-peptide complex is the basis for T cell-mediated immune surveillance and is central to many cancer immunotherapies[3][5][9]. Tumors can evade immune detection by downregulating MHC expression or altering antigen processing pathways, which is a major focus of research and therapeutic intervention[3][5][9]. The biology of MHC-presented tumor antigens underpins the efficacy of immune checkpoint inhibitors, cancer vaccines, and adoptive T cell therapies in oncology. This "target" is not a conventional protein or gene but a functional complex essential for immune-based cancer therapy, hence the entry is flagged as incorrect for a typical drug target database, but critical in immuno-oncology research.

Other names

Tumor antigen presented by major histocompatibility complexMHC-presented tumor antigenMHC-restricted tumor antigen

Recognition of MHC-tumor antigen complexes by cytotoxic T lymphocytes (CD8+ T cells) leading to tumor cell killing - Immune checkpoint blockade enhances T cell recognition or effector function against cells displaying MHC-bound tumor antigens